Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer: a Single-arm, Prospective Trial

NCT05645094 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05645094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05645094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer: a Single-arm, Prospective Trial
Lead sponsor
Fudan University
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2023
Completion date
June 1, 2026
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal carcinoma, msi-high